Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?

Journal of medical virology - 1 Jan 2013

Lee Guan Huei, Aung Myat Oo, Dan Yock Young, Lee Yin Mei, Mak Belinda, Low How Cheng, Lim Kieron, Thwin Maung Aye, Tan Poh Seng, Lim Seng Gee

Abstract excerpt

Entecavir switch is one of the treatment options for lamivudine-resistant hepatitis B (HBV) patients in Asia. This study examined the outcome of patients with different baseline resistance genotypes in a cohort study. In this study, 14 patients with chronic HBV were treated with entecavir 1 mg/day for 5 years. Enrolment criteria include: documented lamivudine resistant mutations, treatment with adefovir 10 mg/day...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asia
Share to Blood Chemical Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Lamivudine

Share to Liver Function Tests

Share to Mutation Rate

Share to RNA-Directed DNA Polymerase

Source

Identifiers

PMID: 23023992
DOI: 10.1002/jmv.23392

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?PMID 23023992Read ↗

The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus.Semantic proximity Read ↗

Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance.Semantic proximity Read ↗

Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.Semantic proximity Read ↗

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.Semantic proximity Read ↗

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.Semantic proximity Read ↗

Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.Semantic proximity Read ↗

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.Semantic proximity Read ↗

Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience.Semantic proximity Read ↗

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.